human papillomavirus bivalent vaccine

Cervarix is a bivalent, recombinant, adjuvanted vaccine developed by GSK for the prevention of diseases caused by human papillomavirus (HPV) types 16 and 18. The vaccine contains virus-like particles (VLPs) composed of the L1 capsid proteins of HPV-16 and HPV-18, which are produced using a recombinant baculovirus expression system in insect cells. It is formulated with GSK's proprietary AS04 adjuvant system, which consists of aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (MPL). MPL acts as a Toll-like receptor 4 (TLR4) agonist, enhancing the immune response and promoting high, sustained levels of neutralizing antibodies. Cervarix is indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grades 1-3, and adenocarcinoma in situ, primarily in females.

Brand names

Cervarix

Other names

HPV-16/18 AS04-adjuvanted vaccineHPV 16/18 L1 VLP AS04 vaccinehuman papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)